perrigo co. Resources | BNET
On GameFAQs: The top 50 most popular games!

BNET Industries

Perrigo Co. (PRGO) is in the Pharma Industry

Revenue
Jun 28 2008
$1.8B
Profit
Jun 28 2008
$135.7M
Market Cap
Sep 03 2008
$3.2B

Latest News and Analysis

Additional Resources

  • Perrigo Reports Record Sales, Earnings and Cash Flow from Operations for Fiscal 2008

    - Full year revenue increased $375 million, or 26 percent, to a record $1.8 billion, including $500 million for the fourth quarter - GAAP net income for the full year increased 84 percent to $135.8 million, or $1.43 per share - Adjusted net income for the...

    Articles 2008-08-18

  • Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference

    ALLEGAN, Mich., Aug. 5 /PRNewswire-FirstCall/ -- Perrigo Company announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday, August 7, at 11:00 a.m. ET at the Southampton Inn in Southampton, New York. The presentation will be...

    Articles 2008-08-05

  • Perrigo Company Will Release Fiscal Year 2008 Results on August 18, 2008

    ALLEGAN, Mich., Aug. 5 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it will release financial results for its fiscal year 2008 on Monday, August 18, 2008 at approximately 8:00 a.m. ET. The Company will conduct a conference call at 10:00 a.m. ET hosted by Joseph C. Papa, Perrigo's...

    Articles 2008-08-05

  • Perrigo to Grow in Michigan

    Company focused on producing quality, affordable healthcare ALLEGAN, Mich., July 15 /PRNewswire-FirstCall/ -- Perrigo Company , the world's largest manufacturer of over-the-counter healthcare products sold under the store-brand label, announced today its intent to invest $10.5 million to expand its facilities at its world headquarters in Allegan,...

    Articles 2008-07-15

  • Smith and Nephew - appoints Non-Executive Director

    Smith & Nephew appoints Non-Executive Director10 July 2008Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technologybusiness, announces the appointment of an additional Non-ExecutiveDirector to the Board.Joseph C. Papa, aged 52, and based in Michigan is Chairman of PerrigoCompany. Perrigo is a leading global healthcare supplier that...

    Articles 2008-07-10

  • Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference

    ALLEGAN, Mich., July 7 /PRNewswire-FirstCall/ -- Perrigo Company announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference on Tuesday, July 8, at 4:05 p.m. ET at the Four Seasons Hotel in Boston....

    Articles 2008-07-07

  • High Growth Reported for the World Smoking Cessation Aids Market

    Reportlinker.com announces that a new market research report related to the Personal care industry is available in its catalogue. World Smoking Cessation Aids Market http://www.reportlinker.com/p090576/World-Smoking-Cessation-Aids-Market.html This report analyzes the worldwide markets for Smoking Cessation Aids in US$ Million. The major product segments analyzed are...

    Articles 2008-07-02

  • Perrigo Announces Approval for Rx Cetirizine Syrup

    ALLEGAN, Mich., June 19 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup Rx only, 1mg/mL. The product is comparable to McNeil Consumer Healthcare's ZyrtecR Syrup, 1mg/mL, indicated...

    Articles 2008-06-19

  • Perrigo Confirms Filing for Generic Version of VANOS®

    ALLEGAN, Mich., June 9 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it has filed an Abbreviated New Drug Application ANDA for Fluocinonide Cream 0.1%, a generic version of VANOSR Cream 0.1%. The Company believes that it is the first to file an ANDA with a Paragraph...

    Articles 2008-06-09

  • Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008

    - Third quarter revenue increased $141 million, or 39 percent, to $504 million on important new product launches - GAAP net income increased 134 percent to $40 million, or $0.42 per share - Adjusted net income increased 100 percent to $44 million, or $0.47 per share...

    Articles 2008-05-06

  • Extreme Fitness Brings on Producer to Showcase Products.

    M2 PRESSWIRE-13 March 2008-InvestSource Inc.: Extreme Fitness Brings on Producer to Showcase ProductsC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 Stocks in the News: Extreme Fitness, Inc. (OTC: EXTF), Perrigo Company (NASDAQ: PRGO), Wyeth (NYSE: WYE), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX),...

    Articles 2008-03-13

  • Perrigo Company Receives Final Approval on Clobetasol Propionate Foam

    Court Issues Temporary Restraining Order ALLEGAN, Mich., March 11 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Clobetasol Propionate Foam, 0.05%. The product is...

    Articles 2008-03-11

  • Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets

    ALLEGAN, Mich., Mar. 6 /PRNewswire-FirstCall/ -- Perrigo Company today announced that its partner, Teva Pharmaceutical Industries Ltd. , has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for over-the-counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets, 5 mg/120 mg. ...

    Articles 2008-03-06

  • Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets

    ALLEGAN, Mich., March 4 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at the same dose as Prilosec OTCR. Under terms of an agreement between Dexcel Pharma...

    Articles 2008-03-04

  • Over-the-counter cetirizine hydrochloride tablets

    Perrigo Company recently reported that the FDA has granted final approval for the manufacturing and marketing of over-the-counter cetirizine hydrochloride tablets (5 mg and 10 mg). This product will be available under store brand labels, and is the generic equivalent of McNeil Consumer Healthcare's Zyrtec[R...

    Articles 2008-03-01

  • page 1 of 1
  • Incorporated: 1987
  • CEO: Mr. Joseph C. Papa

Perrigo is a healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. Co. is the manufacturer of OTC pharmaceutical products for the store brand market. Co.'s primary markets and locations of manufacturing and logistics operations are the U.S., Israel, Mexico and the U.K. Co. has three reportable segments, aligned primarily by product: Consumer Healthcare, Rx Pharmaceuticals and API. Co. also has an Other category that includes two operating segments: Israel Consumer Products; and Israel Pharmaceutical and Diagnostic Products.

Key Competitors

advertisement
Perrigo Co. Company Info

Board of Directors

Mr. David T. Gibbons

Executive Chairman

Ms. Ellen Hoffing

Mr. Moshe Arkin

Dr. Ben-Zion Zilberfarb Ph.D.

Ms. Laurie Brlas

Mr. Gary M. Cohen

Mr. Ran Gottfried

Mr. Michael J. Jandernoa

Mr. Gary K. Kunkle Jr.

Mr. Herman Morris Jr.

Contact Information

515 Eastern Avenue

Allegan, MI

http://www.perrigo.com

269 673-8451

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement
Click Here